Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BufferGel + diaphragm is a contraceptive combination product consisting of an acid-buffering vaginal gel (BufferGel) used in conjunction with a vaginal diaphragm. Developed by ReProtect LLC in collaboration with Johns Hopkins University, the gel's active ingredient is Carbopol 974P (carbomer 974P), a high molecular weight, cross-linked polyacrylic acid. BufferGel is formulated at a pH of 3.9 to maintain the natural protective acidity of the vagina, which is typically neutralized by alkaline semen. By maintaining this acidity, the product inactivates sperm and various sexually transmitted pathogens, including HIV, HSV-1, HSV-2, and *Neisseria gonorrhoeae*. It has been evaluated in Phase III clinical trials as a microbicide and a non-hormonal contraceptive, demonstrating non-inferiority to nonoxynol-9 when used with a diaphragm.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BufferGel + diaphragm.